9661SCleaved Caspase3 Asp175 Antibody and 10 more items

Virginia Commonwealth University (VCU) awarded a contract to Cell Signaling Technology on August 4, 2026, for the supply of monoclonal and polyclonal antibodies for research purposes. The contract, identified as A236_P0346101, carries a cumulative value of $2,986.05 and encompasses eleven distinct antibody products to be delivered to VCU Procurement in Virginia. The antibodies procured include Cleaved Caspase3 Asp175 (available in two sizes), c-Myc, Vinculin E1E9V, CD11c D1V9Y, p38 MAPK, N-Cadherin D4R1H, Phospho-FAK Tyr397 D20B1, Vimentin D21H3, Phospho-p38 MAPK Thr180Tyr182 D3F9, and FAK antibodies, with individual unit prices ranging from $115.60 to $724.20.

The procurement represents a straightforward materials purchase in support of VCU's research operations, with all line items specified as single-unit acquisitions. No specific period of performance or annual value breakdown is delineated in the contract documentation. Cell Signaling Technology has been established as the prime contractor for this award, with all deliverables designated for receipt at VCU Procurement facilities within the Commonwealth of Virginia.